Latest Listings And Ipos News

Aurumin Limited’s shares will be suspended from trading following court approval of Brightstar Resources’ acquisition scheme, marking a pivotal step in the takeover process.

Critica Limited has completed the first tranche of its $8 million placement, issuing over 203 million shares to accelerate development at its Jupiter rare earths project. The second tranche awaits shareholder approval in January 2026.

Rox Resources has successfully completed the first tranche of a $200 million capital raise, issuing 188.7 million shares at 35 cents each. The second tranche, worth $134 million, awaits shareholder approval in December.

Nufarm Finance (NZ) Limited reported a modest 1.1% rise in net profit to $20.53 million for the year ended September 2025, alongside increased distributions to security holders and maintained strong liquidity backed by its parent company.

Aurumin Limited’s acquisition by Brightstar Resources has been legally approved, triggering a share exchange and imminent delisting from the ASX.

Anson Resources has raised A$14 million through a well-supported placement to advance its lithium and uranium projects in Utah, signaling strong investor confidence in its development strategy.

Infragreen Group Limited has reported a strong FY25 performance, exceeding prospectus forecasts with $18.6 million in pro forma EBITDA and a successful $40 million IPO. The company projects robust growth in FY26, driven by organic expansion and strategic acquisitions in sustainable infrastructure.

Lodestar Minerals has responded to ASX queries clarifying the timing and disclosure of key assay results from its Ned’s Creek gold project and detailed the procedural steps behind its Arizona Mountain Pass rare earths acquisition.

Black Bear Minerals has completed the acquisition of the high-grade Shafter Silver Project in Texas, including $150 million in existing infrastructure, positioning itself strategically amid rising silver demand and geopolitical supply shifts.

Lynch Group Holdings shareholders have overwhelmingly approved a $269 million acquisition scheme by Hasfarm, offering a 23% premium on recent share prices. The deal awaits final court approval before completion in December 2025.

Lynch Group Holdings Limited shareholders convened to vote on a proposed $2.155 per share acquisition by Hasfarm Bidco, with strong board and expert backing. The scheme offers a significant premium and awaits final court approval.

Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.